# Pedro Mendes‐Bastos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pedro-mendes-bastos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,827 |
| Field | Dermatology and Skin Diseases |
| h-index | 19 |
| i10-index | 33 |
| Last Known Institution | Hospital do Desterro |
| OpenAlex ID | https://openalex.org/A5084120831 |
| ORCID iD | 0000-0002-2439-920X |
| Works | 119 |

## Researcher papers

- [Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials](https://scholariq.org/papers/secukinumab-in-moderate-to-severe-hidradenitis-suppurativa-sunshine-and-sunrise/)
- [Update on Atopic Dermatitis](https://scholariq.org/papers/update-on-atopic-dermatitis/)
- [Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study](https://scholariq.org/papers/drug-survival-of-il-12-23-il-17-and-il-23-inhibitors-for-psoriasis-treatment-a/)
- [Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions](https://scholariq.org/papers/bruton-s-tyrosine-kinase-inhibition-an-emerging-therapeutic-strategy-in-immune/)
- [Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study](https://scholariq.org/papers/drug-survival-of-interleukin-il-17-and-il-23-inhibitors-for-the-treatment-of/)
- [Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-upadacitinib-treatment-in-adolescents-with-moderate-to/)
- [<scp>Real‐world</scp> clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study](https://scholariq.org/papers/scp-real-world-scp-clinical-psychosocial-and-economic-burden-of-atopic/)
- [Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials](https://scholariq.org/papers/characterization-of-acne-associated-with-upadacitinib-treatment-in-patients-with/)
- [Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)](https://scholariq.org/papers/efficacy-and-safety-of-upadacitinib-versus-dupilumab-in-adults-and-adolescents/)
- [Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study](https://scholariq.org/papers/secukinumab-drug-survival-in-patients-with-psoriasis-a-multicenter-real-world/)
- [The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal](https://scholariq.org/papers/the-apolo-study-a-cross-sectional-analysis-of-disease-characteristics-and/)
- [Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD](https://scholariq.org/papers/multidimensional-burden-of-moderate-to-severe-atopic-dermatitis-in-adolescent/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Hidradenitis Suppurativa and Treatments](https://scholariq.org/topics/hidradenitis-suppurativa-and-treatments/)

## Researcher university

- [Hospital do Desterro](https://scholariq.org/institutions/hospital-do-desterro/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.